BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24722062)

  • 21. HOXB13 mutation and prostate cancer: studies of siblings and aggressive disease.
    Witte JS; Mefford J; Plummer SJ; Liu J; Cheng I; Klein EA; Rybicki BA; Casey G
    Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):675-80. PubMed ID: 23396964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Two Novel HOXB13 Germline Mutations in Portuguese Prostate Cancer Patients.
    Maia S; Cardoso M; Pinto P; Pinheiro M; Santos C; Peixoto A; Bento MJ; Oliveira J; Henrique R; Jerónimo C; Teixeira MR
    PLoS One; 2015; 10(7):e0132728. PubMed ID: 26176944
    [TBL] [Abstract][Full Text] [Related]  

  • 23. G84E mutation in HOXB13 is firmly associated with prostate cancer risk: a meta-analysis.
    Huang H; Cai B
    Tumour Biol; 2014 Feb; 35(2):1177-82. PubMed ID: 24026887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Nyberg T; Govindasami K; Leslie G; Dadaev T; Bancroft E; Ni Raghallaigh H; Brook MN; Hussain N; Keating D; Lee A; McMahon R; Morgan A; Mullen A; Osborne A; Rageevakumar R; ; Kote-Jarai Z; Eeles R; Antoniou AC
    Eur Urol; 2019 May; 75(5):834-845. PubMed ID: 30527799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
    Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
    Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The expression profile and prognostic value of SPINK1 in initially diagnosed bone metastatic prostate cancer.
    Pan X; Zhang X; Gong J; Tan J; Yin X; Tang Q; Shu K; Shen P; Zeng H; Chen N
    Prostate; 2016 Jun; 76(9):823-33. PubMed ID: 27159572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
    Zabalza CV; Adam M; Burdelski C; Wilczak W; Wittmer C; Kraft S; Krech T; Steurer S; Koop C; Hube-Magg C; Graefen M; Heinzer H; Minner S; Simon R; Sauter G; Schlomm T; Tsourlakis MC
    Oncotarget; 2015 May; 6(14):12822-34. PubMed ID: 25825985
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
    Laitinen VH; Wahlfors T; Saaristo L; Rantapero T; Pelttari LM; Kilpivaara O; Laasanen SL; Kallioniemi A; Nevanlinna H; Aaltonen L; Vessella RL; Auvinen A; Visakorpi T; Tammela TL; Schleutker J
    Cancer Epidemiol Biomarkers Prev; 2013 Mar; 22(3):452-60. PubMed ID: 23292082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer.
    Alanee S; Shah S; Vijai J; Schrader K; Hamilton R; Rau-Murthy R; Sarrel K; Manschreck C; Eastham J; Offit K
    Fam Cancer; 2013 Dec; 12(4):597-600. PubMed ID: 23475555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?
    Smith SC; Tomlins SA
    Clin Cancer Res; 2014 Sep; 20(18):4733-6. PubMed ID: 24944315
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
    Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
    BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).
    Xu J; Lange EM; Lu L; Zheng SL; Wang Z; Thibodeau SN; Cannon-Albright LA; Teerlink CC; Camp NJ; Johnson AM; Zuhlke KA; Stanford JL; Ostrander EA; Wiley KE; Isaacs SD; Walsh PC; Maier C; Luedeke M; Vogel W; Schleutker J; Wahlfors T; Tammela T; Schaid D; McDonnell SK; DeRycke MS; Cancel-Tassin G; Cussenot O; Wiklund F; Grönberg H; Eeles R; Easton D; Kote-Jarai Z; Whittemore AS; Hsieh CL; Giles GG; Hopper JL; Severi G; Catalona WJ; Mandal D; Ledet E; Foulkes WD; Hamel N; Mahle L; Moller P; Powell I; Bailey-Wilson JE; Carpten JD; Seminara D; Cooney KA; Isaacs WB;
    Hum Genet; 2013 Jan; 132(1):5-14. PubMed ID: 23064873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.
    Huang KC; Bégin LR; Palanisamy N; Donnelly B; Bismar TA
    Urol Oncol; 2016 May; 34(5):235.e1-10. PubMed ID: 26725250
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of SPINK1 in ETS rearrangement-negative prostate cancers.
    Tomlins SA; Rhodes DR; Yu J; Varambally S; Mehra R; Perner S; Demichelis F; Helgeson BE; Laxman B; Morris DS; Cao Q; Cao X; Andrén O; Fall K; Johnson L; Wei JT; Shah RB; Al-Ahmadie H; Eastham JA; Eggener SE; Fine SW; Hotakainen K; Stenman UH; Tsodikov A; Gerald WL; Lilja H; Reuter VE; Kantoff PW; Scardino PT; Rubin MA; Bjartell AS; Chinnaiyan AM
    Cancer Cell; 2008 Jun; 13(6):519-28. PubMed ID: 18538735
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Prognostic significance of mutually exclusive expression of ERG and SPINK1 in endocrine-treated prostatic cancer].
    Teng L; Gao W; Lu D; Xu J; Zhao L
    Zhonghua Bing Li Xue Za Zhi; 2014 Mar; 43(3):149-53. PubMed ID: 24842011
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies.
    Beebe-Dimmer JL; Hathcock M; Yee C; Okoth LA; Ewing CM; Isaacs WB; Cooney KA; Thibodeau SN
    Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1366-72. PubMed ID: 26108461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A high-density tissue microarray from patients with clinically localized prostate cancer reveals ERG and TATI exclusivity in tumor cells.
    Lippolis G; Edsjö A; Stenman UH; Bjartell A
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):145-50. PubMed ID: 23459095
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
    Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
    J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between germline homeobox B13 (HOXB13) G84E allele and prostate cancer susceptibility: a meta-analysis and trial sequential analysis.
    Zhang J; Xiao L; Qin Z; Xu A; Zhao K; Liang C; Miao C; Zhu J; Chen W; Hua Y; Liu Y; Zhang C; Yu Y; Su S; Wang Z
    Oncotarget; 2016 Oct; 7(41):67101-67110. PubMed ID: 27626483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.